Metropolis Healthcare delivered inline 4Q26 results with 23% revenue growth and upgraded medium-term guidance. Goldman Sachs maintains its Sell rating citing high valuation even as it raised the price target to Rs500.
Key Takeaways
- 1.4Q26 results were largely in line with expectations, with Sales and EBITDA growing 23% and 29% YoY respectively.
- 2.Management raised medium-term topline growth guidance to 13-15%, driven by 8-9% volume growth and improved realization.
- 3.The company targets a sustainable group EBITDA margin of 27-28% over the next 2-3 years through efficiency gains.
Table of Contents
- Topline growth driven by both volume as well as realisation
- Network expansion plans
- Acquired business
- Forward commentary
- Valuation
- Price Target Risks and Methodology - Metropolis Healthcare
- Disclosure Appendix
- Price target and rating history chart(s)
- Regulatory disclosures
Document Preview
Access the Full Report
Get unlimited access to institutional research reports with a 14-day free trial.
Authors
Shyam Srinivasan, CFAKaran Vora, CFA
Securities
Metropolis Healthcare
Themes
Diagnostic Lab Growth DynamicsM&A Integration in Healthcare
Regions
Asia PacificIndia